Biotechnology White Paper
May 6, 2024
Exposure to innovative and transformative biotechnology companies has been a part of Pinnacle’s SMID investment strategy since our portfolio’s inception in 1996. Without a doubt, some of our most successful investments have come from this industry. Surprisingly, we have learned over the years that most investment managers avoid biotech stocks due to the inherent binary risks that come with drug development.
Important Disclosure
Contact Us
Oops! Something went wrong while submitting the form.
- or -
Book a Call With Us Today
Founded in 1984, Pinnacle Associates, Ltd. is a forward thinking, multi-billion dollar investment advisory firm focused on transparency and putting clients first. We provide advice to individuals and families, institutional investors and other financial institutions.
